Pharmaceutical output at Soha Pharmaceutical Company, a subsidiary of the Iranian Red Crescent Medical Procurement Organization, rose by 66% in November 2025 compared to the same period last year, marking a significant expansion in production capacity and operational efficiency.
According to the Public Relations and
International Affairs Unit of the Medical Procurement Organization, Soha
Pharmaceutical Company—affiliated with the Iranian Red Crescent Medical
Procurement Organization—was able to increase its output of medicines,
including tablets, capsules, and liquid formulations, by approximately 66%
during the November–December 2025 period compared to the same timeframe last
year. This accomplishment demonstrates more effective utilization of production
lines and the advancement of manufacturing processes in line with international
standards.
Human health and product quality have always
been the guiding principles of this company’s activities. Soha’s pharmaceutical
production is carried out in compliance with GMP requirements and ISO standards,
ensuring the quality and safety of medicines. This approach plays a significant
role in strengthening the national healthcare system and meeting patients’
needs.